Vietnam explores RNA technology for cancer vaccines
Tam Anh Research Institute and the RNA Institute at the University of New South Wales (UNSW), Australia, are collaborating on RNA-based biomedical research, including potential vaccines for lung cancer, colorectal cancer and influenza.
Vietnam and Australia have inked a cooperation agreement to explore the potential of RNA technology in developing cancer vaccines. The agreement was signed during State President To Lam's state visit to Australia from August 9 to 12. The partnership focuses on two key programs: developing an mRNA influenza vaccine and personalized cancer vaccines for lung and colorectal cancer patients, major health issues in Vietnam and the Asia-Pacific region.
This marks the first time a Vietnamese research institute, Tam Anh Research Institute, is partnering with an institute specializing in RNA biomedical platforms at a top Australian university. The agreement aims to jointly invest, research, and publish products, with a focus on joint training, expert exchanges, research protocols, and RNA technology development.
Professor Pall Thordarson, director of the UNSW RNA Institute, highlighted the importance of the partnership in strengthening Vietnam's capabilities in RNA research, preclinical development, production, Good Manufacturing Practice standards, and clinical trials. He emphasized the value of jointly generating data and solutions tailored to the disease characteristics of Vietnamese and Southeast Asian populations.
Tam Anh Research Institute sees this partnership as a stepping stone to become more proficient in RNA technology, a strategic platform underpinning many next-generation vaccines, biologics, and therapies. The institute aims to participate more deeply in the value chain of this rapidly growing biotechnology sector.
The partnership not only aims to help Vietnam develop expertise across the RNA technology chain, from research and development to clinical applications and potential domestic manufacturing, but also to position Vietnam as a center of design and evaluation for diseases and population groups that have not received adequate attention from the global research chain.
Vietnam's experience with mRNA vaccine clinical trials, its mature vaccine regulatory system, and its extensive research infrastructure make it a promising participant in RNA research in the Asia-Pacific region. The partnership is expected to bolster Vietnam's biomedical sector and bolster domestic expertise in RNA-based vaccines and therapies.
Written by urgent.news from VnExpress International's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
